These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 17617138)

  • 21. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.
    Kane CJ; Bassett WW; Sadetsky N; Silva S; Wallace K; Pasta DJ; Cooperberg MR; Chan JM; Carroll PR
    J Urol; 2005 Mar; 173(3):732-6. PubMed ID: 15711258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity is not predictive of overall survival following permanent prostate brachytherapy.
    Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Adamovich E
    Am J Clin Oncol; 2007 Dec; 30(6):588-96. PubMed ID: 18091052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity and risk of biochemical failure for patients receiving salvage radiotherapy after prostatectomy.
    King CR; Spiotto MT; Kapp DS
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1017-22. PubMed ID: 18707829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
    Yu HH; Song DY; Tsai YY; Thompson T; Frassica DA; DeWeese TL
    Urology; 2007 Jul; 70(1):111-6. PubMed ID: 17656219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
    Bañez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
    J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer.
    Strom SS; Kamat AM; Gruschkus SK; Gu Y; Wen S; Cheung MR; Pisters LL; Lee AK; Rosser CJ; Kuban DA
    Cancer; 2006 Aug; 107(3):631-9. PubMed ID: 16802288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy.
    Pierorazio PM; Lambert SM; Matsukhani M; Sprenkle PC; McCann TR; Katz AE; Olsson CA; Benson MC; McKiernan JM
    BJU Int; 2007 Nov; 100(5):1066-70. PubMed ID: 17784880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database.
    Freedland SJ; Bañez LL; Sun LL; Fitzsimons NJ; Moul JW
    Prostate Cancer Prostatic Dis; 2009; 12(3):259-63. PubMed ID: 19581922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
    Loeb S; Yu X; Nadler RB; Roehl KA; Han M; Hawkins SA; Catalona WJ
    J Urol; 2007 Jan; 177(1):102-6; discussion 106. PubMed ID: 17162013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy.
    Imamoto T; Suzuki H; Fukasawa S; Shimbo M; Inahara M; Komiya A; Ueda T; Shiraishi T; Ichikawa T
    Eur Urol; 2005 Mar; 47(3):308-12. PubMed ID: 15716191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
    BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.
    Taira AV; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1143-9. PubMed ID: 19117691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relationship between serum prostate-specific antigen levels and body mass index in Beijing men over 50 years of age].
    Wang Y; Zhou Z; Tian Y; Shao Q; Chen S; Hong BF; Zhang XH; Ren XH; Sun WX; Wang ZW; Na YQ
    Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(24):1681-3. PubMed ID: 19957525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer.
    Petit JH; Chen MH; Loffredo M; Sussman B; Renshaw AA; D'Amico AV
    Cancer; 2006 Nov; 107(9):2180-5. PubMed ID: 17009323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?
    Phillips JJ; Hall MC; Lee WR; Clark PE
    Urol Oncol; 2007; 25(3):196-200. PubMed ID: 17483015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
    Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
    Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.